T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer.
HER2-positive Advanced Breast Cancer
DRUG: Ribociclib Oral Tablet
Objective Response Rate (ORR), ORR is defined as the percentage of patients who achieved a best overall response of Complete Response (CR) or Partial Response (PR), per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions as assessed by the Investigator: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters., up to 54 months
Progression-Free Survival (PFS), From date of first dose until the date of first documented progression or date of death from any cause, whichever came first., up to 54 months|2-year Overall Survival (OS), the overall survival rate in all patients from the date of first dose to the end of follow-up at 2 years., up to 54 months|Objective Response Rate of Subgroup Population (ORR), Objective Response Rate of subgroup population (ER\>=10% vs ER\<10%), up to 54 months|Adverse Event (AE), Evaluation performed using the National Cancer Institute (NCI)- Standard for Common Terminology for Adverse Events (CTCAE)v.5.0., up to 54 months
This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety of Trastuzumab Emtansine (T-DM1) combined with CDK4/6 inhibitor Ribociclib in the treatment of unresectable locally advanced or metastatic HER2-positive breast cancer.